Clopilet 75

Generic

Clopidogrel Bisulphate

 

Indications

In patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], it is advised to reduce the rate of myocardial infarction (MI) and stroke. In individuals with acute ST-elevation myocardial infarction, it is used to lower the risk of myocardial infarction and stroke (STEMI).

Patients with established peripheral arterial disease or a history of recent MI, stroke, or established Peripheral Arterial Disease: Patients with established peripheral arterial disease or a history of recent MI, stroke, or established Peripheral Arterial Disease.

 

Pharmacology

Clopidogrel is a prodrug that is used to treat blood clots. The irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets suppresses platelet activation and aggregation. Platelet aggregation inhibition is dose-dependent and visible 2 hours after single oral dosages. On the first day, repeated 75 mg doses decrease ADP-induced platelet aggregation, and inhibition achieves a stable state between Days 3 and 7.

 

Dosage & Administration 

Acute Coronary Syndrome: In patients who need an antiplatelet effect within hours, initiate Clopilet with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg once daily. Initiating it without a loading dose will delay the establishment of an antiplatelet effect by several days.

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: 75 mg once daily orally without a loading dose.

 

Interaction

NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): CYP2C19 inhibitors (omeprazole or esomeprazole): Increases the risk of bleeding. Avoid taking omeprazole or esomeprazole at the same time.

Repaglinide (substrates for CYP2C8): Clopidogrel should not be taken with Repaglinide since it raises Repaglinide plasma level.

 

Contraindications

Clopilet should not be used if you have any of the following conditions: Hypersensitivity to the medicine or any of the product's components. Peptic ulcer or cerebral hemorrhage are examples of active pathological bleeding.

 

Side Effects

Clopilet is a generally well-tolerated drug.

Common side effects: Bleeding, Diarrhoea, gastrointestinal discomfort, haemorrhage, Skin reactions.

Rare side effects: Acquired haemophilia, anaemia, angioedema, arthralgia, arthritis, bone marrow disorders.

 

Pregnancy & Lactation

In pregnant women, there are no sufficient and well-controlled trials. It should only be used during pregnancy if absolutely necessary. Clopidogrel is not known to be excreted in human breast milk. Considering the medicine's value to the mother, a decision should be taken whether to quit nursing or discontinue the drug.

 

Precautions & Warnings

Clopidogrel should not be used if you have any of the following conditions: Because tA is a prodrug, genetic polymorphisms in CYP2C19 (a poor metabolizer) and medicines that inhibit CYP2C19, such as Omeprazole and Esomeprazole, hinder metabolism to its active metabolite. Clopidogrel's antiplatelet action may be reduced if it is taken with certain medications or if you have a CYP2C19 poor metaboliser.

The risk of bleeding may increase since it inhibits platelet aggregation during the platelet's whole lifetime (7-10 days). Platelet transfusions given within 4 hours of the loading dosage or 2 hours of the maintenance dose may be less efficient in restoring hemostasis.

The risk of bleeding increases if you stop using Clopidogrel.

 

Therapeutic Class

Anti-platelet drugs

 

Storage Conditions

Do not store at temperatures above 30°C. Keep out of children's reach.

 

Pharmaceutical Name

Sun Pharmaceutical Ltd.

 

Related Products

• Pladex 75
• Preclot
• Clont
• Odrel
• Clognil 75